record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.
Mark A. Mintun; Albert Lo; Cynthia Evans; Alette M. Wessels; Paul Ardayfio; Scott W. Andersen; Sergey Shcherbinin; JonDavid Sparks. New England Journal of Medicine 2021. doi:10.1056/NEJMoa2100708 · curator_source · 10.1056/NEJMoa2100708
conditions
Provenance
source title
Mark A. Mintun; Albert Lo; Cynthia Evans; Alette M. Wessels; Paul Ardayfio; Scott W. Andersen; Sergey Shcherbinin; JonDavid Sparks. New England Journal of Medicine 2021. doi:10.1056/NEJMoa2100708
doi
10.1056/NEJMoa2100708
pmid
33720637
journal
New England Journal of Medicine
authors
Mark A. Mintun, Albert Lo, Cynthia Evans, Alette M. Wessels, Paul Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks
Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.
vs_58f995dd73dc0057 · source:Mark A. Mintun; Albert Lo; Cynthia Evans; Alette M. Wessels; Paul Ardayfio; Scott W. Andersen; Sergey Shcherbinin; JonDavid Sparks. New England Journal of Medicine 2021. doi:10.1056/NEJMoa2100708|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_00bd89051d105094finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_4f1dbc7414c2957bfinding.reviewedTRAILBLAZER-ALZ Phase II (Mintun et al., NEJM 2021) was the foundational signal that donanemab clears amyloid plaques. Agent-drafted accept; eligible for human re-review.
agent:vela-curation-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_0c933959d5dd71abfinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_fe1facc0dc7a30c2finding.reviewTRAILBLAZER-ALZ Phase II (Mintun et al., NEJM 2021) was the foundational signal that donanemab clears amyloid plaques. Agent-drafted accept; eligible for human re-review.
applied · agent:vela-curation-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation record targets this finding id.